secukinumab low dose + secukinumab high dose
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Chronic Plaque-type Psoriasis
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Trial Timeline
Aug 29, 2018 → Sep 12, 2023
NCT ID
NCT03668613About secukinumab low dose + secukinumab high dose
secukinumab low dose + secukinumab high dose is a phase 3 stage product being developed by Novartis for Moderate to Severe Chronic Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03668613. Target conditions include Moderate to Severe Chronic Plaque-type Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03668613 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Chronic Plaque-type Psoriasis